Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti CD52 monoclonal antibody, coding sequence and use thereof

A monoclonal antibody, CDR2 technology, applied in the medical field, can solve the problems of unsatisfactory characteristics such as monoclonal antibody specificity

Inactive Publication Date: 2004-06-30
SHANGHAI ZHANGJIANG BIOTECH CO LTD
View PDF0 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] At present, although a variety of monoclonal antibodies against CD52 antigen have been obtained at home and abroad, the specificity and other characteristics of these monoclonal antibodies are not ideal

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] Screening the Variable Region Genes of Anti-CD52 Antibody from Antibody Library

[0049] 1) Construction of human antibody library

[0050] According to Marks et al. J. Mol. Biol., 222, 581-597; Hoogenboom and Winte, J. Mol. Biol., 227, 381-388; Haidaris CG et al., J Immunol Methods. 2001 Nov 1; 257 (1- 2): 185-202; Griffiths, A.D. et al. EMBO J., 13, 3245-3260 (1994); Nissim, A. et al. The method described in EMBO J., 13, 692-698 (1994) to construct a human antibody library . In short, the genes of heavy and light chains of immunoglobulins were prepared from peripheral blood lymphocytes, amplified in vitro by PCR, and cloned into phage vectors. CD52 protein (purchased from Shenzhen Jingmei Company) was used as the antigen, and the corresponding specific antibody was screened.

[0051] 2) screening

[0052] Add 1 ml of the revived antibody library strain to 14 ml of fresh LB medium, and culture in a 50 ml Erlenmeyer flask at 37°C for 16 hours.

[0053] Centrifuge a...

Embodiment 2

[0061] Cloning of Expression Vectors for Antibody Variable Region Coding Sequences

[0062] The cloned bacterial strain obtained in Example 1 was amplified in 100 ml of LB medium, and the plasmid DNA was purified with a plasmid DNA extraction and purification kit from Promega Company.

[0063] After digesting the above plasmid DNA with XbaI and NheI, the digested fragments were separated on 1.5% agarose gel electrophoresis, and a band of about 350 bp was taken for gel recovery, and the resulting fragment was the heavy chain variable region coding sequence.

[0064] The above plasmid DNA was digested with HindIII and BsiWI, and the digested fragments were separated on 1.5% agarose gel electrophoresis, and a band of about 320 bp was taken for gel recovery, and the resulting fragment was the light chain variable region coding sequence.

[0065] Then first insert the above heavy chain variable region coding sequence into the expression vector pMG18-3K (see book DEVELOPMENT OF TOOL...

Embodiment 3

[0067] Transfection of CHO cells and screening of recombinant clones

[0068] The expression vector with the antibody gene constructed in the above-mentioned Example 2 was transferred into the Escherichia coli DH5α strain, and then inoculated in 100 milliliters of LB medium for amplification, and the ultrapure plasmid DNA purification kit (Ultrapure Plasmid DNA) from Qiagen Company was used to Purification Kit) to extract and purify plasmid DNA. The above-mentioned purified plasmid DNA was transfected into CHO cells using the liposome method kit of Invitrogen Company, and the operation was performed according to the manufacturer's instructions.

[0069] The transformed CHO cells were continuously selected on the selection medium for 9 weeks, and finally cultured in extreme dilution on a 96-well plate for 3 consecutive times for monoclonalization.

[0070] The selected monoclonal cell lines were cultured on RPM1641 medium, and Western Blotting experiments were performed on the...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides an anti-CD52 specific monoclonal antibody. Said monoclonal antibody has good stability and strong specificity, and is specially applicable for preventing and curing graft rejection reaction and curing chronic lymphocyte leukosis. Said invention also provides the preparation method of said monoclonal antibody and medicine composition containing said monoclonal antibody.

Description

technical field [0001] The present invention relates to the field of medicine. More specifically, the present invention relates to specific monoclonal antibodies against CD52 and applications thereof. The antibody of the present invention is very useful for prevention and treatment of transplant rejection. Background technique [0002] At present, organ transplantation technology has become an effective and routine treatment for end-stage organ failure. However, the biggest problem with organ transplantation is immune rejection. In organ transplants, especially kidney, liver, heart, lung and bone marrow transplants, it is necessary to reduce the immune system's rejection of the transplant. Many immunosuppressants have been developed and have been clinically successful, including steroids, azathioprine, and cyclosporin A, for example. But they all have to be strictly controlled to avoid unwanted side effects. An added complication is that immunosuppression predisposes th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61P37/06C07K16/44C12N15/13
Inventor 马菁
Owner SHANGHAI ZHANGJIANG BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com